Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-473-7700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.07 million
Profitability
Miscellaneous
Employees18
OptionableOptionable
Geron (NASDAQ:GERN) Frequently Asked Questions
What is Geron's stock symbol?
Geron trades on the NASDAQ under the ticker symbol "GERN."
How were Geron's earnings last quarter?
Geron Co. (NASDAQ:GERN) released its quarterly earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.05) by $0.02. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.22 million. Geron had a negative return on equity of 19.16% and a negative net margin of 3,077.78%. View Geron's Earnings History.
When is Geron's next earnings date?
What price target have analysts set for GERN?
5 brokerages have issued 12-month target prices for Geron's stock. Their predictions range from $1.80 to $7.00. On average, they anticipate Geron's stock price to reach $4.01 in the next year. This suggests a possible upside of 170.9% from the stock's current price. View Analyst Price Targets for Geron.
What is the consensus analysts' recommendation for Geron?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Geron.
Has Geron been receiving favorable news coverage?
News articles about GERN stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Geron earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the next several days.
Are investors shorting Geron?
Geron saw a increase in short interest in January. As of January 31st, there was short interest totalling 35,227,714 shares, an increase of 2.3% from the January 15th total of 36,046,089 shares. Based on an average daily trading volume, of 2,101,947 shares, the days-to-cover ratio is currently 16.8 days. Currently, 19.0% of the shares of the stock are short sold. View Geron's Current Options Chain.
Who are some of Geron's key competitors?
Some companies that are related to Geron include Amphastar Pharmaceuticals (AMPH), Wave Life Sciences (WVE), Deciphera Pharmaceuticals (DCPH), Vanda Pharmaceuticals (VNDA), Puma Biotechnology (PBYI), Rhythm Pharmaceuticals (RYTM), Epizyme (EPZM), Tricida (TCDA), Kiniksa Pharmaceuticals (KNSA), Alder Biopharmaceuticals (ALDR), MacroGenics (MGNX), CannTrust (CNTTF), Homology Medicines (FIXX), Advanz Pharma (CXRXF) and Retrophin (RTRX).
Who are Geron's key executives?
Geron's management team includes the folowing people:
- Dr. John A. Scarlett, CEO, Pres & Chairman (Age 68)
- Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 50)
- Dr. Andrew J. Grethlein, Exec. VP & COO (Age 55)
- Mr. Stephen N. Rosenfield, Exec. VP & Chief Legal Officer (Age 69)
- Ms. Melissa A. Kelly Behrs, Exec. VP & Chief Bus. Officer (Age 55)
Who are Geron's major shareholders?
Geron's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.07%), Northern Trust Corp (1.16%), Geode Capital Management LLC (1.02%), Two Sigma Investments LP (0.53%), Millennium Management LLC (0.40%) and Bank of New York Mellon Corp (0.38%). Company insiders that own Geron stock include Robert J Spiegel and Stephen Rosenfield. View Institutional Ownership Trends for Geron.
Which major investors are selling Geron stock?
GERN stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, New York State Common Retirement Fund, Bank of New York Mellon Corp, Jane Street Group LLC and Raymond James Financial Services Advisors Inc.. Company insiders that have sold Geron company stock in the last year include Robert J Spiegel and Stephen Rosenfield. View Insider Buying and Selling for Geron.
Which major investors are buying Geron stock?
GERN stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Two Sigma Investments LP, D. E. Shaw & Co. Inc., Ibex Investors LLC, Virtu Financial LLC, Northern Trust Corp and Virtus ETF Advisers LLC. View Insider Buying and Selling for Geron.
How do I buy shares of Geron?
Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Geron's stock price today?
One share of GERN stock can currently be purchased for approximately $1.48.
How big of a company is Geron?
Geron has a market capitalization of $275.80 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,910,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Geron employs 18 workers across the globe.
What is Geron's official website?
How can I contact Geron?
Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]
MarketBeat Community Rating for Geron (NASDAQ GERN)
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.
